Wellington Management Group’s Aquestive Therapeutics AQST Stock Holding History

Wellington Management Group’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Buy	301,647 +11,587	+4%	+$48.8K	﹤0.01%	1708
2026 Q1	$1.2M	Buy	290,060 +19,084	+7%	+$77.5K	﹤0.01%	1643
2025 Q4	$1.75M	Sell	270,976 -14,801	-5%	-$92.2K	﹤0.01%	1624
2025 Q3	$1.6M	Buy	285,777 +40,478	+17%	+$175K	﹤0.01%	1691
2025 Q2	$812K	Buy	245,299 +39,755	+19%	+$114K	﹤0.01%	1749
2025 Q1	$596K	Buy	205,544 +25,932	+14%	+$78.5K	﹤0.01%	1795
2024 Q4	$639K	Sell	179,612 -5,579	-3%	-$25.7K	﹤0.01%	1800
2024 Q3	$922K	Buy	+185,191	New	+$721K	﹤0.01%	1727

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Wellington Management Group's AQST Position: Q2 2026 in Review

Wellington Management Group increased its Aquestive Therapeutics (AQST) stake by 4% in Q2 2026, buying an estimated $48.8K and bringing the position to 301,647 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Wellington Management Group first reported a position in AQST in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.75M in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Wellington Management Group held 301,647 shares of Aquestive Therapeutics worth $1.25M as of Q2 2026.
Wellington Management Group bought 11,587 Aquestive Therapeutics shares in Q2 2026, an estimated $48.8K.
Aquestive Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1708 holding.
Wellington Management Group first reported a position in Aquestive Therapeutics in Q3 2024 and has held it in 8 quarters since.
Wellington Management Group's Aquestive Therapeutics position peaked at $1.75M in Q4 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.